Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;48(6):273-287.
doi: 10.1136/rapm-2022-104097. Epub 2023 Mar 30.

Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain

Affiliations
Review

Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain

Harsha Shanthanna et al. Reg Anesth Pain Med. 2023 Jun.

Abstract

Spinal cord stimulation (SCS) has demonstrated effectiveness for neuropathic pain. Unfortunately, some patients report inadequate long-term pain relief. Patient selection is emphasized for this therapy; however, the prognostic capabilities and deployment strategies of existing selection techniques, including an SCS trial, have been questioned. After approval by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, a steering committee was formed to develop evidence-based guidelines for patient selection and the role of an SCS trial. Representatives of professional organizations with clinical expertize were invited to participate as committee members. A comprehensive literature review was carried out by the steering committee, and the results organized into narrative reports, which were circulated to all the committee members. Individual statements and recommendations within each of seven sections were formulated by the steering committee and circulated to members for voting. We used a modified Delphi method wherein drafts were circulated to each member in a blinded fashion for voting. Comments were incorporated in the subsequent revisions, which were recirculated for voting to achieve consensus. Seven sections with a total of 39 recommendations were approved with 100% consensus from all the members. Sections included definitions and terminology of SCS trial; benefits of SCS trial; screening for psychosocial characteristics; patient perceptions on SCS therapy and the use of trial; other patient predictors of SCS therapy; conduct of SCS trials; and evaluation of SCS trials including minimum criteria for success. Recommendations included that SCS trial should be performed before a definitive SCS implant except in anginal pain (grade B). All patients must be screened with an objective validated instrument for psychosocial factors, and this must include depression (grade B). Despite some limitations, a trial helps patient selection and provides patients with an opportunity to experience the therapy. These recommendations are expected to guide practicing physicians and other stakeholders and should not be mistaken as practice standards. Physicians should continue to make their best judgment based on individual patient considerations and preferences.

Keywords: back pain; chronic pain; pain management; spinal cord stimulation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: HS, RC, JK, JR, CJW: None. SE: Received consultancy fees from Medtronic, Mainstay Medical, Boston Scientific Corp, and Saluda Medical. He has received department research funding from the National Institute of Health Research, Medtronic Ltd, and Boston Scientific. DAP: Editor for Reg Anesth Pain Med. Consulted for Avanos, Boston Scientific, Medtronic, Nevro, and SI BONE. Pain Diagnostics and Interventioal Care has received research support from Avanos, Medtronic, Nevro, Stimgenics, and Abbott. BB: Consultancy agreement with Medtronic Switzerland. Department has received unrestricted research grants from Medtronic Switzerland. EB: Consultancy agreement with Medtronic Switzerland. Department has received unrestricted research grants from Medtronic Switzerland. TD: Biohaven Pharmaceuticals (coinvestigator in clinical trial of rimegepant for trigeminal neuralgia). RD: Consultancy fees from Boston Scientific Corp, Mainstay Medical, Medtronic and Saluda Medical for work unrelated with the role and conduct of trial stimulation on spinal cord stimulation (SCS) therapy for chronic pain patients. CH: Institutional research grants from Nevro. FH: Consultancy fees from Abbott, Saluda, Salvia, Pfizer; Research grants from Zonmw, STW, VWS, Abbott, Medtronic, Saluda, Boston Scientific (Investigator initiated studies). LK: Consulting from Avanos, Institutional Funding from Avanos and FUS Mobile. RN: Dr North’s previous employers, including Johns Hopkins University, and the charitable nonprofit Neuromodulation Foundation, of which he is an unpaid officer, have received grant support and income from industry, including Abbott, Boston Scientific, Medtronic, Nevro, Algostim/Nuvectra, and Stimwave. He holds over 30 patents in the field of neuromodulation, and currently receives royalties from Abbott. SN: Editor for Reg Anesth Pain Med.

Similar articles

Cited by

References

    1. Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the neuromodulation appropriateness consensus Committee. Neuromodulation: Technology at the Neural Interface 2014;17:515–50. - PubMed
    1. Dworkin RH, O’Connor AB, Kent J, et al. Interventional management of neuropathic pain: neupsig recommendations. Pain 2013;154:2249–61. - PMC - PubMed
    1. Katz N, Dworkin RH, North R, et al. Research design considerations for randomized controlled trials of spinal cord stimulation for pain: initiative on methods, measurement, and pain assessment in clinical trials/institute of neuromodulation/international neuromodulation Society recommendations. Pain 2021;162:1935–56. - PMC - PubMed
    1. Harmsen IE, Hasanova D, Elias GJB, et al. Trends in clinical trials for spinal cord stimulation. Stereotact Funct Neurosurg 2021;99:123–34. - PubMed
    1. Jones CMP, Shaheed CA, Ferreira G, et al. Spinal cord stimulators: an analysis of the adverse events reported to the Australian therapeutic goods administration. J Patient Saf 2022;18:507–11. - PMC - PubMed

Substances